Kura Oncology, Inc.

NASDAQ:KURA

Biotechnology

Healthcare
$7.34 +0.73%

+$0.07 today

Market cap
$674.39M
Beta
0.36
P/E (TTM)
-2.9
EPS (TTM)
-$3.32
52W Low $5.45High $12.49

Volume 2.46M

Average 1.66M

KURA Pre-Tax Margin

Income before tax as a percentage of revenue.

Kura Oncology, Inc.NASDAQ: KURA

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to -401.5%

Pre-tax margin was -401.5% in Q1 FY2026, up 4.0 pp from a year earlier. On a trailing-twelve-month basis it was -411.1%, down 146.9 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-401.5%+65.4 pp QoQ
Last fiscal yearDec 2025
-412.5%-93.4 pp YoY
LTMMar 2026
-411.1%-146.9 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+4.0 pp——
1 year-93.4 pp——
3 years———
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-412.5%
Year-over-year change
-93.4pp

Pre-Tax Margin vs competitors

How KURA compares with its peers on the latest reported figures

  • KURA's LTM Mar 2026 pre-tax margin of -411.1% is the 6th highest of the 7 companies compared; the peer median is -35.7%.
  • Its year-over-year change of -146.9 pp is the 6th highest of 7, against a peer median of +215.2 pp.
KURA Competitors Peer median
Pre-Tax Margin for KURA and competitors
Company Period LTM level YoY 3-year change
HCMHUTCHMED (China) LimitedLTM Jun 202588.8% +95.0 pp+179.5 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202643.9% +335.5 pp+152.9 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202640.7% +21.9 pp+90.1 pp
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-112.0% +645.5 pp—
VSTMVerastem, Inc.LTM Mar 2026-391.2% +1095.8 pp+2165.7 pp
KURAKura Oncology, Inc.LTM Mar 2026-411.1% -146.9 pp—
CRDFCardiff Oncology, Inc.LTM Mar 2026-8526.1% -217.6 pp+2294.9 pp
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
TYRATyra Biosciences, Inc.FY2025— ——
ORICORIC Pharmaceuticals, Inc.FY2025— ——
BBOTBridgeBio Oncology Therapeutics Inc.FY2025— ——
Peer median (excluding KURA) -35.7%+215.2 pp+179.5 pp

Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00053.88M67.48M
Cost of Revenue00849K057K
Gross Profit00(849K)53.88M67.43M
Gross Margin———100.0%99.9%
Research & Development84.72M92.81M115.24M169.97M251.07M
Selling, General & Admin46.54M47.05M50.57M77.11M119.98M
Operating Expenses131.26M139.87M164.96M247.08M371.06M
Depreciation & Amortization558K759K849K848K1.03M
EBITDA(129.49M)(134.85M)(150.23M)(169.5M)(275.83M)
EBITDA Margin———-314.6%-408.7%
Operating Income(131.26M)(139.87M)(165.8M)(193.2M)(303.63M)
Operating Margin———-358.5%-449.9%
Interest Income1.21M4.25M14.72M22.85M26.77M
Interest Expense414K229K1.55M1.62M1.51M
Other Income / Expenses792K4.03M13.17M21.23M25.26M
Income Before Tax(130.47M)(135.84M)(152.63M)(171.97M)(278.37M)
Pre-Tax Margin———-319.1%-412.5%
Income Tax Expense0002.02M297K
Net Income(130.47M)(135.84M)(152.63M)(173.98M)(278.67M)
Net Margin———-322.9%-412.9%
EPS (Basic)(1.97)(2.03)(2.08)(2.02)(3.18)
EPS (Diluted)(1.97)(2.03)(2.08)(2.02)(3.18)
Weighted Avg Shares66.35M66.99M73.23M86.16M87.68M
Weighted Avg Shares (Diluted)66.35M66.99M73.23M86.16M87.68M

Kura Oncology, Inc.

NASDAQ:KURA

Intrinsic Alpha fair value

Locked

Current Price

$7.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.